ClinicalTrials.gg
RecruitingNCT07826429Updated Oct 16, 2026

Evaluation of the F&P Mask, US, 2026

An interventional study of F&P Licorice Mask in Chronic Respiratory Conditions and Obstructive Sleep Apnea (OSA), sponsored by Fisher and Paykel Healthcare. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Treatment

Updated Oct 13, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

This clinical investigation is designed to validate and confirm the overall performance, safety, usability, reliability, and acceptability of the F\&P PAP mask in a home environment.

02

Conditions studied

  • Chronic Respiratory Conditions
  • Obstructive Sleep Apnea (OSA)
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 45 is below the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Fisher and Paykel Healthcare is the lead sponsor of 86 studies on the registry; 16 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ≥22 years of age
  • Weigh ≥66 pounds
  • Have been prescribed PAP/NIV therapy by a physician
  • Are an existing PAP/NIV therapy mask user with ≥3 months of use prior to enrolment in the clinical investigation*
  • Are compliant with PAP/NIV therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical investigation
  • Are fluent in spoken and written English
  • Possess the capacity to provide

Exclusion criteria

Exclusion Criteria:

  • Are intolerant to PAP/NIV therapy
  • Possess, or suffer from, anatomical or physiological conditions which make PAP/NIV therapy inappropriate
  • Are required to use PAP/NIV therapy for >12 hours per day or for extensive periods, not including sleep or naps
  • Are trying to get pregnant, are pregnant, or think they may be pregnant
  • Have an IPAP pressure of >30 cmH2O if on BPAP
  • Use a PAP/NIV therapy device for the delivery of medicines, except supplemental O2
  • Use a PAP/NIV therapy device that does not possess data recording capabilities to capture AHI and a numerical indicator of leak that is accessible to the clinical investigation site
  • Have a history of light-induced seizures (for optional anthropometric scan only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Other
    Intervention

    Single-arm, non-randomised, open-label

    Device: F&P Licorice Mask

Interventions

  • DeviceF&P Licorice Mask

    PAP/NIV Therapy Mask

06

What researchers measure

Primary outcomes

  1. Therapeutic Efficacy

    Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe AHI is measured by dividing the total number of recorded apneas (complete breathing stops) and hypopneas (shallow breathing episodes) by the total number of hours a person slept during an overnight sleep study or using a PAP device. Higher AHI values represent worse outcomes. There is no maximum theoretical index score.

    Time frame: Baseline and 14±5 days

  2. Epworth Sleepiness Scale

    All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

    Time frame: 14±5 days

  3. Patient and Clinical Global Impression (PGI/CGI)

    Determined by Patient Global Impression (PGI) and Clinical Global Impression (CGI) assessments completed at baseline and Day 14. Baseline symptom severity is assessed using a 6-point scale (1 = No symptoms to 6 = Very severe symptoms). Change from baseline is assessed using a 7-point scale (1 = Very much better to 7 = Very much worse; 4 = No change). Higher severity scores indicate worse symptoms. For change assessments, lower scores indicate improvement and higher scores indicate worsening. PGI is completed by the patient and CGI is completed by the investigator/clinician.

    Time frame: Baseline and 14±5 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Apr 2027, 6 months later.

Of 115 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 6 months is below that.

Counting every sponsor, half of 623 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Sep 17, 2026
StartEst.
Sep 28, 2026
Primary completionEst.
Apr 21, 2027
CompletionEst.
Jun 21, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
Clayton Sleep Institute is now Recruiting
Oct 13, 2026
Contact
Study contact changed: S•••@fphcare.com · •••3912→c•••@fphcare.co.nz · •••6485. See the current contact
Oct 13, 2026
Title
Evaluation of the F&P Licorice Mask, US, 2026
Oct 13, 2026
Show all 2 updates
  1. Oct 16, 2026
    Minor edits only
    + 2 other changes: identifiers and description
  2. Oct 13, 2026
    Not yet recruiting→Recruiting
    Clayton Sleep Institute is now Recruiting
    Contact Study contact changed: S•••@fphcare.com · •••3912→c•••@fphcare.co.nz · •••6485. See the current contact
    Title Evaluation of the F&P Licorice Mask, US, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07826429
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Sep 28, 2026 (estimated)
Primary completion
Apr 21, 2027 (estimated)
Completion
Jun 21, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Clinical Research Scientist
Contact
cpap.trial@fphcare.co.nz
+6421436485

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion